Exhibit 99.1 Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update · Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA (bevacizumab gamma) · United Kingdom (UK) Marketing Authorization Application (MAA) submitted · NORSE EIGHT fully underway in the US; Topline readout expected in Q4 CY2024 · Resubmission of the ONS-5010 Biologics License Application (BLA) ...